Cannabidiol - Zynerba Pharmaceuticals

Drug Profile

Cannabidiol - Zynerba Pharmaceuticals

Alternative Names: Cannabidiol gel patch; Cannabidiol transdermal gel; CBD; CBD gel patch; CBD transdermal gel; Synthetic CBD; Topical cannabidiol gel; Topical CBD gel; Transdermal CBD gel; ZYN002

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zynerba Pharmaceuticals
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Heart failure therapies; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Fragile X syndrome
  • Phase II Epilepsy
  • Preclinical Alcoholism; Drug abuse; Rheumatoid arthritis
  • Discontinued Osteoarthritis

Most Recent Events

  • 12 Jul 2018 Safety and efficacy data from a phase II trial in Fragile X syndrome released by Zynerba Pharmaceuticals
  • 09 Jul 2018 Phase-II/III clinical trials in Fragile X syndrome (In adolescents, In children) in New Zealand, Australia (Transdermal) (ACTRN-12618001063202)
  • 09 Jul 2018 Phase-II/III clinical trials in Fragile X syndrome (In adolescents, In children) in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top